You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

cell

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia Trial in Duarte, Atlanta (procedure, drug,

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • +9 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +7 more
  • Duarte, California
  • +1 more
Sep 22, 2023

Sickle Cell Disease, COVID-19 Vaccine, Vaccine Hesitancy Trial in Durham (SCD-specific COVID-19 vaccination information (SCVI)

Not yet recruiting
  • Sickle Cell Disease
  • +2 more
  • SCD-specific COVID-19 vaccination information (SCVI) video
  • Durham, North Carolina
    Duke Adult Sickle Cell Program
Aug 17, 2023

NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

Not yet recruiting
  • NK Cell
  • +2 more
  • autologous NK cell
  • Hubei, Xiangyang, China
    EC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023

Merkel Cell Carcinoma Clinical Trial Engagement Patterns

Not yet recruiting
  • Merkel Cell Carcinoma
    • San Francisco, California
      Power Life Sciences
    Sep 8, 2023

    Clear Cell Renal Cell Carcinoma Trial in Los Angeles (89Zr-DFO-girentuximab)

    Available
    • Clear Cell Renal Cell Carcinoma
    • 89Zr-DFO-girentuximab
    • Los Angeles, California
      UCLA
    Oct 12, 2023

    Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • circulating tumoral DNA detection
    • Rouen, France
      Centre Henri Becquerel
    Oct 13, 2023

    Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

    Recruiting
    • Cutaneous T-cell Lymphoma
    • Linperlisib in combined with Chidamide
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Sep 8, 2023

    d to Reveal Heterogeneity of Secondary Hyperparathyroidism

    Not yet recruiting
    • Secondary Hyperparathyroidism
    • Single-cell sequencing
    • (no location specified)
    Nov 12, 2023

    Delving Into Participation Trends in Renal Cell Carcinoma

    Not yet recruiting
    • Renal Cell Carcinoma
      • San Francisco, California
        Power Life Sciences
      Oct 16, 2023

      T-Cell and NK-Cell Tumor Trial

      Not yet recruiting
      • T-Cell and NK-Cell Neoplasm
        • (no location specified)
        Sep 28, 2023

        Lymphoma, Peripheral Blood Stem Cell Transplantation Trial (Eltrombopag olamine)

        Not yet recruiting
        • Lymphoma
        • Peripheral Blood Stem Cell Transplantation
        • Eltrombopag olamine
        • (no location specified)
        Jul 25, 2023

        Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

        Recruiting
        • Peripheral T Cell Lymphoma
        • +2 more
        • Chidamide combined with Duvillisib
        • Xiamen, Fujian, China
          The First Affiliated Hosptial of Xiamen University
        Nov 28, 2023

        Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)

        Not yet recruiting
        • Clear Cell Renal Cell Carcinoma
        • 68Ga-NY104 PET/CT
        • Beijing, Beijing, China
          Peking Union Medical College Hospital
        May 28, 2023

        Needs and Preferences of Patients With Head-neck Cutaneous SCC

        Active, not recruiting
        • Cutaneous Squamous Cell Carcinoma
        • +10 more
        • Regular care with additional administration of a semi-structured interview
        • Maastricht, Netherlands
          Maastricht University Medical Center+
        Sep 13, 2023

        Esophageal Squamous Cell Carcinoma Trial in Wuhan (no intervention)

        Recruiting
        • Esophageal Squamous Cell Carcinoma
        • no intervention
        • Wuhan, Hubei, China
          Renmin hosptial of Wuhan University
        Jul 29, 2023

        Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis Trial (Alendronate Sodium)

        Not yet recruiting
        • Sickle Cell Disease
        • +4 more
        • Alendronate Sodium
        • (no location specified)
        Sep 6, 2023

        Renal Cell Carcinoma Trial in Guangzhou (Pucotenlimab Combined With Lenvatinib)

        Not yet recruiting
        • Renal Cell Carcinoma
        • Pucotenlimab Combined With Lenvatinib
        • Guangzhou, Other (Non U.s.), China
          Sun Yat-sen University Cancer Center
        Nov 10, 2023

        Sickle Cell Disease, Chronic Pain Trial (Quantitative sensory testing)

        Not yet recruiting
        • Sickle Cell Disease
        • Chronic Pain
        • Quantitative sensory testing
        • (no location specified)
        Nov 15, 2023

        Predict T Cell Chimerism After MSD SCT for SCD?

        Recruiting
        • Sickle Cell Disease
        • Alemtuzumab Injection [Campath]
        • Amsterdam, Netherlands
          Amsterdam Medical Centre
        Jun 20, 2023

        Esophageal Squamous Cell Carcinoma Trial in Shanghai (Sintilimab, Chemotherapy)

        Not yet recruiting
        • Esophageal Squamous Cell Carcinoma
        • Shanghai, Shanghai, China
          Fudan University Shanghai Cancer Center
        Nov 30, 2023

        Renal Cell Carcinoma Trial in Houston (Tivozanib, Nivolumab)

        Not yet recruiting
        • Renal Cell Carcinoma
        • Houston, Texas
          M D Anderson Cancer Center
        Sep 19, 2023

        Patient Perspectives in Mantle Cell Lymphoma Clinical Research

        Not yet recruiting
        • Mantle Cell Lymphoma
          • San Francisco, California
            Power Life Sciences
          Sep 15, 2023

          High-Dose Methotrexate Clearance in Diffuse Large B-Cell

          Recruiting
          • Central Nervous System Lymphoma
          • Diffuse Large B-Cell Lymphoma
          • Non-Interventional Study
          • Columbus, Ohio
            Ohio State University Comprehensive Cancer Center
          Sep 8, 2023

          Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

          Not yet recruiting
          • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
          • (no location specified)
          Sep 5, 2023

          Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

          Not yet recruiting
          • Cancer
          • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
          • Fludarabine (30 mg/m^2)
          • +2 more
          • (no location specified)
          Jul 25, 2023